Clinical Trials

88 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04978584 2026-04-15

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04458610 2026-03-20

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

47 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

53 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

33 enrolled 16 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01880567 2026-02-19

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

113 enrolled

Lymphoma, Mantle-Cell

NCT03147612 2026-02-17

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

22 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03710772 2026-02-11

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

30 enrolled

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

50 enrolled

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT01959698 2026-01-28

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

29 enrolled 19 charts

Lymphoma, Large B-Cell, Diffuse

NCT03808610 2026-01-09

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

50 enrolled

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02427620 2025-11-21

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT04765111 2025-11-10

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

53 enrolled

Lymphoma, Mantle-Cell

NCT02007044 2025-11-06

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT04479267 2025-09-29

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

8 enrolled

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04665765 2025-09-03

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

41 enrolled 12 charts

Lymphoma, Large B-Cell, Diffuse

NCT03505762 2025-08-20

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

80 enrolled

Lymphoma, B-Cell

NCT01318317 2025-04-25

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

8 enrolled 13 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT02628405 2024-07-01

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

30 enrolled 15 charts